NCT05746520

Brief Summary

To demonstrate the safety, efficacy, and feasibility of short-course post-operative antibiotic treatment for simple and complicated appendicitis

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
268

participants targeted

Target at P75+ for not_applicable

Timeline
Completed

Started Mar 2023

Typical duration for not_applicable

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

February 16, 2023

Completed
11 days until next milestone

First Posted

Study publicly available on registry

February 27, 2023

Completed
3 days until next milestone

Study Start

First participant enrolled

March 2, 2023

Completed
2.3 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

June 18, 2025

Completed
1 month until next milestone

Study Completion

Last participant's last visit for all outcomes

July 21, 2025

Completed
Last Updated

November 3, 2025

Status Verified

January 1, 2025

Enrollment Period

2.3 years

First QC Date

February 16, 2023

Last Update Submit

October 30, 2025

Conditions

Keywords

post-operative antibioticsacute appendicitiscomplicated appendicitis

Outcome Measures

Primary Outcomes (1)

  • Number of participants with no antibiotic related adverse effects

    All subjects will be contacted at least 30 days after appendectomy by telephone if unable to contact subject, then electronic medical record will be reviewed. Outcomes will be assessed by Desirability of Outcome Ranking (DOOR), with the lowest ranking of 1 indicating no adverse effects. Infectious/antibiotic complications requiring antibiotic treatment only, Emergency Department visit, hospital readmission, percutaneous drainage, operative intervention, and death ranked 2 through 7. A lower score indicates a more desirable outcome. For subjects of same DOOR score, Response Adjusted for Duration of Antibiotic Risk (RADAR) scores will be used to determine the better outcome. The distribution of DOOR scores and associated statistical analyses will be reported.

    Day 30

Secondary Outcomes (1)

  • Incidence of Infectious/Antibiotic Complications

    Day 30

Study Arms (4)

Restricted Post-Operative Antibiotics Group

EXPERIMENTAL

Participants undergoing standard of care (SOC) with simple appendicitis will not receive post-operative antibiotics. Participants undergoing standard of care (SOC) with complicated (gangrenous or perforated) appendicitis will receive 24 hours of SOC post-operative antibiotics.

Other: Antibiotic

Restricted Duration of SOC Antibiotic Use

OTHER

Use of Standard of Care Antibiotics, type as determined by the clinician, will be restricted to none or 24 hours of post-operatively.

Other: Antibiotic

Liberal Post-Operative Antibiotics Group

ACTIVE COMPARATOR

Participants undergoing standard of care (SOC) with simple appendicitis will receive 24 hours of post-operative antibiotics. Participants undergoing standard of care (SOC) with complicated (gangrenous or perforated) appendicitis will receive 4 days of SOC post-operative antibiotics.

Other: Antibiotic

Liberal Duration of SOC Antibiotic Use

OTHER

Use of Standard of Care Antibiotics, type as determined by the clinician, will be permitted for 24 hours or 4 days of post-operatively.

Other: Antibiotic

Interventions

Type of antibiotic is per clinical judgement with the duration being the experimental aspect of this study.

Also known as: antibiotics are per standard of care (SOC)
Liberal Duration of SOC Antibiotic UseLiberal Post-Operative Antibiotics GroupRestricted Duration of SOC Antibiotic UseRestricted Post-Operative Antibiotics Group

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Age ≥ 18 years
  • Planned appendectomy (laparoscopic or open)
  • Willing and able to provide informed consent
  • Working telephone number or reliable method to contact patient after hospital discharge

You may not qualify if:

  • Unable to consent
  • Pregnant Women
  • Prisoners
  • immunocompromised as determined by clinical team, or patients actively receiving steroids, chemotherapy, or immunosuppressing medications (for example tacrolimus), or patients with active hematologic malignancy affecting the immune system, leukopenia, or end-stage Acquired immunodeficiency syndrome (AIDS)
  • Heart Failure
  • Allergy to Bupivacaine
  • Unlikely to comply with treatment or follow-up
  • Inpatient consultation for appendicitis
  • Clinically suspected sepsis based on Sepsis-3 definition
  • Current use of antibiotics for other indications
  • Type 1 Diabetes or uncontrolled hyperglycemia

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Wake Forest University Health Sciences

Winston-Salem, North Carolina, 27157, United States

Location

MeSH Terms

Conditions

Appendicitis

Interventions

Anti-Bacterial Agents

Condition Hierarchy (Ancestors)

Intraabdominal InfectionsInfectionsGastroenteritisGastrointestinal DiseasesDigestive System DiseasesCecal DiseasesIntestinal Diseases

Intervention Hierarchy (Ancestors)

Anti-Infective AgentsTherapeutic UsesPharmacologic ActionsChemical Actions and Uses

Study Officials

  • Rafael Torres Fajardo, MD

    Wake Forest University Health Sciences

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

February 16, 2023

First Posted

February 27, 2023

Study Start

March 2, 2023

Primary Completion

June 18, 2025

Study Completion

July 21, 2025

Last Updated

November 3, 2025

Record last verified: 2025-01

Data Sharing

IPD Sharing
Will share

de-identified data will be shared with Denver health and combined with data from other independent sites for final analysis

Shared Documents
STUDY PROTOCOL
Time Frame
Beginning 9 months and ending 36 months following article publication
Access Criteria
Investigators whose proposed use of the data has been approved by an independent review committee identified for this purpose

Locations